BioTuesdays

Tag - Jason Kolbert

Markets

EF Hutton starts CytoSorbents at buy; PT $10

EF Hutton launched coverage of CytoSorbents (NASDAQ:CTSO) with a “buy” rating and $10 target price. The stock closed at $1.03 on July 26. CytoSorbents’ innovative filter cartridges, CytoSorb, and DrugSorb, stand...

July 29, 2024
Markets

EF Hutton starts Citius Pharmaceuticals at buy; PT $6

EF Hutton launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) a “buy” rating and $6 target price. The stock closed at $0.7340 on July 12. Citius is a pharmaceutical/biotechnology company with two late-stage assets...

July 15, 2024
Can-Fite
Markets

Dawson James ups Can-Fite to buy on valuation call

Dawson James upgraded Can-Fite BioPharma (NYSE American, TASE:CANF) to “buy” from “neutral” with a $6 price target. The stock closed at $1.74 on April 28. Analyst Jason Kolbert writes that the stock is reaching new lows...

May 1, 2023
NRx-Pharma-Logo
Markets

Dawson James ups NRx Pharma PT to $9 from $3

Dawson James Securities raised its price target for NRx Pharmaceuticals (NASDAQ:NRXP) to $9 from $3, saying the company’s NRX-101 drug candidate could change the treatment paradigm for depression, PTSD, and related...

April 3, 2023
NRx-Pharma-Logo
Markets

Dawson James starts NRx Pharma at buy; PT $3.00

Dawson James Securities initiated coverage of NRx Pharmaceuticals (NASDAQ:NRXP) with a “buy” rating and $3.00 price target. The stock closed at 68 cents on March 16. NRx Pharmaceuticals is a clinical-stage...

March 17, 2023
Markets

Dawson James starts Hillstream at buy; PT $4

Dawson James Securities initiated coverage of Hillstream BioPharma (NASDAQ:HILS) with a “buy” rating and price target of $4. The stock closed at $1.24 on Feb. 21. Hillstream is a preclinical biotechnology company...

February 22, 2023
Markets

Dawson James starts Genprex at buy; PT $3

Dawson James Securities initiated coverage of Genprex (NASDAQ:GNPX) with a “buy” rating and $3 price target. The stock closed at $1.34 on Jan. 27. Genprex is a clinical-stage gene therapy company pioneering the...

January 30, 2023
Zomedica Pharmaceuticals
Markets

Dawson James starts Zomedica at buy; PT $6

Dawson James initiated coverage of Zomedica (NYSEA:ZOM) with a “buy” rating and price target of $6. The stock closed at 20 cents on Jan. 5. Analyst Jason Kolbert writes that Zomedica is positioning itself as a leading...

January 6, 2023
Smart for Life Logo
Markets

Dawson James starts Smart for Life at buy; PT $8

Dawson James initiated coverage of Smart for Life (NASDAQ:SMFL) with a “buy” rating and $8 price target. The stock closed at 53 cents on Aug. 26. The company’s goal is the development, marketing, manufacturing...

August 29, 2022